- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07761988
The FamilyStrong Pilot Randomized Trial
Brief Distress Support for Family Caregivers of Persons With Advanced Cancer: The FamilyStrong Pilot Randomized Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a single-site, two-arm, parallel-group, NIH Stage IB pilot randomized clinical trial evaluating FamilyStrong, a brief caregiver distress-screening and support intervention. Sixty adult family caregivers of people with advanced cancer will be randomized 1:1 to FamilyStrong or usual care. The caregiver is the unit of randomization and the direct recipient of the intervention. Up to 60 patients may also participate in research data collection, but patient participation is optional and patients do not receive the FamilyStrong intervention.
Caregivers assigned to FamilyStrong will receive approximately monthly telephone contacts for 24 weeks from a trained lay navigator. During each contact, the navigator will administer the FamilyStrong Caregiver Distress Thermometer and caregiver-specific Problem List, identify the caregiver's highest-priority concerns and desired assistance, and provide individualized support. Support may include emotional support, information and education, collaborative problem-solving, action planning, resource navigation, consultation, or referral to appropriate clinical or community services. Caregivers may accept, decline, or postpone any offered assistance.
FamilyStrong caregivers will also receive the FamilyStrong Navigation Companion, a caregiver-directed resource containing monthly check-in pages, caregiving resources, medical and appointment organizers, problem-solving and action-planning tools, and space for notes. Caregivers assigned to usual care will continue to use services ordinarily available through the cancer center and community. Participants in both groups will receive information about available cancer-center and family-support resources.
Study assessments will occur at baseline and approximately 24 weeks. Intervention-group caregivers will also be invited to complete a post-intervention qualitative interview about their experience with FamilyStrong and the study procedures. As a pilot trial, the study is designed primarily to evaluate acceptability, feasibility, intervention delivery, and the practicality of trial procedures, while estimating preliminary between-group effects to inform a future, larger efficacy trial. It is not powered to provide a definitive test of intervention effectiveness.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sally Engler, MPH
- Numéro de téléphone: 205-996-7564
- E-mail: sengler@uab.edu
Sauvegarde des contacts de l'étude
- Nom: J. Nicholas Odom, PhD, RN
- Numéro de téléphone: 205-934-7597
- E-mail: dionneod@uab.edu
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama at Birmingham
-
Contact:
- Sally Engler, MPH
- Numéro de téléphone: 205-996-7564
- E-mail: sengler@uab.edu
-
Contact:
- James N Odom, PhD, RN
- Numéro de téléphone: 2059347597
- E-mail: dionneod@uab.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
CAREGIVERS:
1) ≥18 years of age; 2) self-endorsing or identified by the patient as "a relative, friend, or partner that has a close relationship with you and who assists with your health and medical care and who may or may not live in the same residence as you and who is not paid for their help"; 3) caring for a patient with advanced-stage cancer (see definition under Patient Inclusion criteria below) who is not enrolled in hospice; 4) caregivers will NOT need to have a patient willing to participate; and 5) able to speak and read English and complete baseline measures.
PATIENTS:
- ≥18 years of age; 2) screened within 60 days of an oncology visit where the patient had documentation of a new diagnosis of an advanced stage cancer, defined as metastatic and/or recurrent/progressive stage III/IV cancer, including brain, lung, breast, gynecologic, head and neck, gastrointestinal, genitourinary cancer, melanoma; and hematologic malignancies; and 3) able to speak and read English and complete baseline measures.
Exclusion Criteria:
CAREGIVERS:
1) Self-reported active, untreated mental illness (i.e., schizophrenia, bipolar disorder, or major depressive disorder), dementia, active suicidal ideation, uncorrected hearing loss, or active substance abuse.
PATIENTS:
- Receiving hospice per EHR; 2) Per EHR, active, untreated mental illness (i.e., schizophrenia, bipolar disorder, or major depressive disorder), dementia, suicidal ideation, uncorrected hearing loss, or substance abuse.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: FamilyStrong
Caregivers randomized to FamilyStrong will receive approximately monthly telephone-based distress screening and individualized support from a trained lay navigator for 24 weeks.
During each encounter, the navigator will administer the FamilyStrong Caregiver Distress Thermometer and Problem List, identify the caregiver's priority concerns and desired assistance, and provide support as appropriate, including emotional support, information and education, collaborative problem-solving, action planning, resource navigation, consultation, or referral.
Participants will also receive the FamilyStrong Navigation Companion, a caregiver-directed resource containing check-in pages, caregiving resources, medical and appointment organizers, worksheets, and notes pages.
Additional follow-up contacts may occur based on caregiver needs.
|
Caregivers randomized to FamilyStrong will receive approximately monthly telephone-based distress screening and individualized support from a trained lay navigator for 24 weeks.
During each encounter, the navigator will administer the FamilyStrong Caregiver Distress Thermometer and Problem List, identify the caregiver's priority concerns and desired assistance, and provide support as appropriate, including emotional support, information and education, collaborative problem-solving, action planning, resource navigation, consultation, or referral.
Participants will also receive the FamilyStrong Navigation Companion, a caregiver-directed resource containing check-in pages, caregiving resources, medical and appointment organizers, worksheets, and notes pages.
Additional follow-up contacts may occur based on caregiver needs.
|
|
Aucune intervention: Usual care
Caregivers randomized to usual care will continue to use the supportive services ordinarily available through the UAB cancer center, health system, community organizations, and their personal support networks.
The study will not restrict access to social work, chaplaincy, behavioral health, palliative care, patient navigation, support groups, or other services.
Participants will receive a study-approved packet describing available cancer-center and family-support resources but will not receive the monthly FamilyStrong navigator contacts during the 24-week study period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Acceptability of FamilyStrong Assessed by the Theoretical Framework of Acceptability Questionnaire
Délai: 24 weeks after randomization
|
Intervention-group caregivers will complete the Theoretical Framework of Acceptability questionnaire, which assesses affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, and self-efficacy.
The outcome will be the mean questionnaire score.
A mean score of at least 4 is the prespecified benchmark indicating acceptable intervention delivery.
|
24 weeks after randomization
|
|
Feasibility: FamilyStrong Intervention Completion Rate
Délai: 24 weeks
|
Percentage of eligible, scheduled FamilyStrong encounters completed by intervention-group caregivers.
A completed encounter includes administration of the Caregiver Distress Thermometer, Problem List, "Bothers Most," and "Would Like Assistance With" questions, with individualized support provided as indicated.
Encounters scheduled after withdrawal or patient death are excluded from the denominator.
The feasibility benchmark is at least 80% completion.
|
24 weeks
|
|
Feasibility: Study Assessment Completion Rate
Délai: 24 weeks
|
Percentage of baseline and 24-week study assessments completed by eligible caregiver and optional patient participants.
Assessments not administered because of patient death or withdrawal will be reported separately and will not be counted as incomplete.
The prespecified feasibility benchmark is at least 80% completion.
|
24 weeks
|
|
Feasibility: Caregiver Retention Rate
Délai: From randomization through the final applicable study activity, approximately 24 weeks
|
Percentage of randomized caregiver participants who remain enrolled through completion of their final protocol-applicable study activity.
Caregivers whose patient dies before week 24 will not be considered lost solely because the week-24 quantitative assessment is not administered.
|
From randomization through the final applicable study activity, approximately 24 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Caregivers: Hospital Anxiety and Depression Scale (anxiety symptoms)
Délai: Baseline and 24 weeks
|
Caregiver anxiety symptoms will be measured using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale.
Subscale scores range from 0 to 21, with higher scores indicating greater anxiety symptoms.
The outcome is the change in score from baseline to 24 weeks after randomization.
|
Baseline and 24 weeks
|
|
Caregivers: Hospital Anxiety and Depression Scale (depressive symptoms)
Délai: Baseline and 24 weeks
|
Caregiver depressive symptoms will be measured using the seven-item depression subscale of the Hospital Anxiety and Depression Scale.
Higher scores indicate greater depressive symptoms.
The outcome is the change in depression subscale score from baseline to 24 weeks after randomization.
|
Baseline and 24 weeks
|
|
Caregivers: PROMIS Global Health 10 (physical health quality of life)
Délai: Baseline and 24 weeks
|
Caregiver physical health-related quality of life will be measured using the physical health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better physical health-related quality of life.
The outcome is the change in score from baseline to 24 weeks after randomization.
|
Baseline and 24 weeks
|
|
Caregivers: PROMIS Global Health 10 (mental health quality of life)
Délai: Baseline and 24 weeks
|
Caregiver mental health-related quality of life will be measured using the mental health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better mental health-related quality of life.
|
Baseline and 24 weeks
|
|
Caregivers: Cancer Survivors' Partners Unmet Needs Measure (CaSPUN)
Délai: Baseline and 24 weeks
|
Caregiver unmet supportive care needs will be measured using the 35-item Cancer Survivors' Partners Unmet Needs Measure (CaSPUN).
The measure assesses unmet needs across information, quality of life, emotional and relationship, and life-perspective domains.
Higher scores indicate greater unmet needs.
|
Baseline and 24 weeks
|
|
Patients: Hospital Anxiety and Depression Scale (anxiety symptoms)
Délai: Baseline and 24 weeks
|
Anxiety symptoms among optional patient participants will be measured using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale.
Higher scores indicate greater anxiety symptoms.
|
Baseline and 24 weeks
|
|
Patients: Hospital Anxiety and Depression Scale (depressive symptoms)
Délai: Baseline and 24 weeks
|
Depressive symptoms among optional patient participants will be measured using the seven-item depression subscale of the Hospital Anxiety and Depression Scale.
Higher scores indicate greater depressive symptoms.
|
Baseline and 24 weeks
|
|
Patients: PROMIS Global Health 10 (physical quality of life)
Délai: Baseline and 24 weeks
|
Physical health-related quality of life among optional patient participants will be measured using the physical health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better physical health-related quality of life.
|
Baseline and 24 weeks
|
|
Patients: PROMIS Global Health 10 (mental health quality of life)
Délai: Baseline and 24 weeks
|
Mental health-related quality of life among optional patient participants will be measured using the mental health score from the 10-item PROMIS Global Health measure.
Higher scores indicate better mental health-related quality of life.
|
Baseline and 24 weeks
|
|
Patients: Cancer Survivors' Unmet Needs Measure (CaSUN)
Délai: Baseline and 24 weeks
|
Unmet supportive care needs among optional patient participants will be measured using the 35-item adapted Cancer Survivors' Unmet Needs Measure (CaSUN).
The measure assesses needs related to information and medical care, quality of life, emotional and relationship concerns, and life perspective.
Higher scores indicate greater unmet needs.
|
Baseline and 24 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- IRB-300017196
- DBG-26-1598921-01-CTPS-W25 (Autre subvention/numéro de financement: American Cancer Society)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .